Yahoo

Bachem (SWX:BANB) Stock Stays Rich After A 60% Run

Bachem Holding has delivered strong recent returns, and that kind of share price strength naturally raises a question for you as an investor. Are the cash flows this business can produce over time enough to justify where the stock trades today, or has sentiment moved ahead of the underlying economics?

  • The stock is up 60.1% over the past year, which puts real pressure on the question of whether today's valuation still matches the cash the company can generate.

  • Bachem's peptide and oligonucleotide manufacturing model depends heavily on capital investment and contract visibility, which can shape how quickly accounting earnings turn into steady, repeatable cash flows for shareholders.

  • What if you looked at Bachem Holding through its earnings instead? See what Bachem Holding's 43.3x P/E says about the price .

The issue now is whether the current share price is in line with the intrinsic value suggested by Bachem Holding's cash flows on a Discounted Cash Flow (DCF) basis.

If you want to cross-check Bachem Holding against other ideas using cash flow and quality filters, a focused screener of 188 high quality undervalued stocks can be a useful next step.

Is Bachem Holding Getting Expensive on Cash Flow?

The Discounted Cash Flow (DCF) work here takes Bachem Holding's forecast cash generation and discounts it back to today in CHF. Latest twelve‑month free cash flow is a loss of CHF 42.3m, and the projections only move into positive territory further out, which signals a business still in a heavy investment phase rather than one already throwing off spare cash.

Analyst estimates in the model point to recovering and then growing free cash flow over the next decade. However, the DCF output still comes in modestly below the current share price of CHF86.00. That gap suggests the market is already pricing in a smooth transition from current cash burn to the healthier cash flows implied later in the model, with limited room for setbacks in project timing or capital spending efficiency. Find out what Bachem Holding could be worth using our Discounted Cash Flow (DCF) estimate .

The Bachem Holding Narrative: What Would Justify Today's Price?

Narratives on Bachem Holding pick up where the DCF puzzle leaves off and spell out which paths for growth, profitability and earnings would need to hold for the stock to be worth materially more or less than today's price. Each one turns Bachem Holding's implied fair value into a thesis you can track over time, rather than a single point estimate, and they sit on Simply Wall St's Community page for you to review.

Community views on Bachem Holding split sharply between a tight-float growth story and a high-expectation execution risk.

Bull case: 66% undervalued

"Bachem is the undisputed backbone of the global peptide supply chain, it is currently the purest public play on the peptide boom…"

Discover why this Narrative puts Bachem Holding at 66% undervalued .

Bear case: 63% overvalued

"Customer prepayments rose to CHF 455m and are used to support a capital expenditure program running at 45 to 48% of sales…"

Explore why this Narrative puts Bachem Holding at 63% overvalued .

The share price is only one piece of the Bachem Holding puzzle

Valuation work tells you what the market is paying for Bachem Holding's cash flows, but your decision also hinges on who is steering the business and how their incentives are structured. See who runs Bachem Holding and how they are paid .

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BANB.SW .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Mobilize your Website
View Site in Mobile | Classic
Share by: